Biotech Retrophin, LLC Files For $40 Million IPO

Published: Dec 20, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Retrophin, which is developing treatments for postpartum milk let-down, Schizophrenia and Autism, filed on Wednesday with the SEC to raise up to $40 million in an initial public offering. The New York, NY-based company, which was founded in 2008, plans to list on the NASDAQ under the symbol RTRX. The company is currently traded on the OTCQB under the same ticker.

Help employers find you! Check out all the jobs and post your resume.

Back to news